The feasibility of transferring this approach into future experimental treatment protocols is underscored by the fact that vinca alkaloids such as VCR are part of standard therapy for NB and that the PLK1 inhibitor BI 6727 as single agent is under evaluation in a phase I clinical trial in pediatric malignancies (http://www.clinicaltrials.gov). This evidence concerns the gene PLK1 and neuroblastoma.